Clofarabine

Generic Name
Clofarabine
Brand Names
Clolar, Evoltra
Drug Type
Small Molecule
Chemical Formula
C10H11ClFN5O3
CAS Number
123318-82-1
Unique Ingredient Identifier
762RDY0Y2H
Background

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...

Indication

For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.

Associated Conditions
Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
Associated Therapies
-
Clinical Trials
Related News

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

First Posted Date
2013-02-20
Last Posted Date
2019-05-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
65
Registration Number
NCT01794702
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

First Posted Date
2012-10-05
Last Posted Date
2024-06-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
64
Registration Number
NCT01701986
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date
2012-10-04
Last Posted Date
2022-09-28
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
80
Registration Number
NCT01700946
Locations
🇺🇸

Rady Children's Hospital and Health Center, San Diego, California, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia

First Posted Date
2012-09-03
Last Posted Date
2017-12-02
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Registration Number
NCT01677949
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia

Phase 2
Completed
Conditions
Leukemia
Interventions
Drug: clofarabine
Drug: cytarabine
First Posted Date
2012-08-02
Last Posted Date
2017-06-20
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
39
Registration Number
NCT01656031
Locations
🇺🇸

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation

First Posted Date
2012-07-18
Last Posted Date
2017-07-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
34
Registration Number
NCT01643668
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

First Posted Date
2012-06-27
Last Posted Date
2019-12-17
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
4
Registration Number
NCT01629082
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Allogeneic Stem Cell Transplant for CLL

First Posted Date
2012-06-27
Last Posted Date
2020-02-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
15
Registration Number
NCT01629511
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

First Posted Date
2012-06-22
Last Posted Date
2017-12-05
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
3
Registration Number
NCT01626092
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

First Posted Date
2012-06-18
Last Posted Date
2017-02-20
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
34
Registration Number
NCT01621477
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy